The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 224,450 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 20.13% since April 8, 2016 and is downtrending. It has underperformed by 25.11% the S&P500.
The move comes after 7 months positive chart setup for the $1.49B company. It was reported on Nov, 14 by Barchart.com. We have $4.23 PT which if reached, will make TSE:PLI worth $983.40 million more.
ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage
Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $6.70 is the highest target while $3 is the lowest. The $4.94 average target is 93.73% above today’s ($2.55) stock price. ProMetic Life Sciences Inc. has been the topic of 18 analyst reports since August 10, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the shares of PLI in a report on Tuesday, December 15 with “Outperform” rating. Scotia Capital maintained it with “Outperform” rating and $5 target price in Thursday, August 11 report. The firm has “Outperform” rating given on Tuesday, December 8 by RBC Capital Markets. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Speculative Buy” rating by TD Securities on Thursday, October 27. RBC Capital Markets maintained ProMetic Life Sciences Inc. (TSE:PLI) on Monday, October 5 with “Outperform” rating. Scotia Capital maintained it with “Outperform” rating and $3 target price in Monday, August 10 report. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by RBC Capital Markets on Thursday, October 27. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, June 15. The rating was maintained by Scotia Capital on Thursday, October 27 with “Outperform”. As per Thursday, August 25, the company rating was maintained by RBC Capital Markets.
More news for ProMetic Life Sciences Inc. (TSE:PLI) were recently published by: Prnewswire.com, which released: “Telesta Therapeutics Inc. announces closing of arrangement with Prometic Life …” on October 31, 2016. Marketwatch.com‘s article titled: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” and published on March 11, 2016 is yet another important article.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.49 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.